Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,965,546 shares of the company’s stock after purchasing an additional 34,069 shares during the quarter. Janus Henderson Group PLC owned about 3.79% of Janux Therapeutics worth $73,961,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after acquiring an additional 2,685 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Janux Therapeutics in the fourth quarter valued at $57,000. ProShare Advisors LLC acquired a new stake in Janux Therapeutics during the 1st quarter valued at $251,000. Lester Murray Antman dba SimplyRich purchased a new stake in Janux Therapeutics during the 1st quarter worth $300,000. Finally, SG Americas Securities LLC purchased a new stake in Janux Therapeutics during the 4th quarter worth $100,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Transactions at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the transaction, the insider now directly owns 3,271,216 shares in the company, valued at $179,099,076. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the sale, the insider now owns 3,271,216 shares in the company, valued at $179,099,076. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Tighe Reardon sold 822,721 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $45,043,974.75. Following the sale, the chief financial officer now directly owns 633,673 shares in the company, valued at $34,693,596.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,000,000 shares of company stock valued at $164,250,000. 35.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JANX has been the topic of a number of analyst reports. Jonestrading began coverage on Janux Therapeutics in a research report on Tuesday, April 16th. They set a “buy” rating and a $70.00 target price on the stock. Wedbush lifted their price objective on shares of Janux Therapeutics from $53.00 to $74.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. HC Wainwright upped their price objective on shares of Janux Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, May 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, May 9th. Finally, Scotiabank initiated coverage on shares of Janux Therapeutics in a research report on Thursday, May 30th. They set a “sector perform” rating and a $47.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.29.

Janux Therapeutics Price Performance

JANX traded down $0.22 during trading on Wednesday, reaching $41.01. 703,609 shares of the stock traded hands, compared to its average volume of 766,742. The stock’s 50-day simple moving average is $43.46 and its two-hundred day simple moving average is $37.12. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The firm had revenue of $1.25 million during the quarter, compared to analyst estimates of $0.98 million. Analysts forecast that Janux Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.